Ind-Swift Laboratories has reported a standalone sales turnover of Rs 249.28 crore and a net loss of Rs 13.55 crore for the quarter ended Dec '13
Ind-Swift Laboratories has reported a standalone sales turnover of Rs 237.93 crore and a net loss of Rs 8.57 crore for the quarter ended Sep '13
With the onset of monsoon, Tulsian is bullish on pesticides, seed chemicals manufacturer-Rallis India. He sees the stock to touch Rs 170 in a six months time range and with very limited downside risk.
Ind-Swift Laboratories has reported a standalone sales turnover of Rs 234.94 crore and a net loss of Rs 12.03 crore for the quarter ended Dec '12
It was a range bound session for the market as the Nifty perked up a bit in late trade to close around 5270. It is still trapped in a 50 point trading range, said Udayan Mukherjee, managing editor of CNBC-TV18.
In CNBC-TV18's popular show Bull's Eye, SP Tulsian, sptulsian.com shares trading strategy of the day.
Ind-Swift Laboratories has reported a sales turnover of Rs 360.69 crore and a net profit of Rs 18.36 crore for the quarter ended Mar '12
Stocks in news: RIL | SML Isuzu | MRPL | Escorts | Essar Shipping | Ind-Swift Labs | Syndicate Bank | Power Grid | SCI | Bank of Maharashtra | PNB | Hindalco and Ankur Drugs are stocks which are in news today.
Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.
In an interview to CNBC-TV18, NK Bansal, CFO of Ind-Swift Labs said the company expects to end the order book with Rs 90 crore from exports and Rs 20 crore from the domestic business. Talking about the mint derivative business, he said, "This year for the menthol business we are expecting a turnover of Rs 50 crore."
Birendra Kumar Singh of FRR Shares feels that one should hold Ind-Swift Labs.
Sunidhi Securities is bullish on Ind-Swift Labs and has recommended buy rating on the stock with a target of Rs 125 in its June 20, 2011 research report.
Ind-Swift Labs has got a phamaceutical and medical devices agency approval from the Japanese government for two drugs. In an interview with CNBC-TV18, Gopal Munjal, Chairman, Ind-Swift Labs spoke on the approval and the investment the facility would require.
Ind-Swift Laboratories has reported a sales turnover of Rs 310.11 crore and a net profit of Rs 24.62 crore for the quarter ended Dec '10